Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy via limited distribution (LD). However, the press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).
Here are several LD deals that have been recently publicly confirmed subsequent to the approvals.
Amber Specialty Pharmacy announces today that they will begin dispensing LENVIMA (lenvatinib). Used by itself, LENVIMA treats differentiated thyroid cancer (DTC) when it can no longer be treated with radioactive iodine, and hepatocellular carcinoma (HCC) when it cannot be removed by surgery. LENVIMA is used with other medications to treat additional types of cancers, including advanced renal cell carcinoma (RCC) and advanced endometrial carcinoma. LENVIMA is manufactured by Eisai.
Biologics by McKesson recently announced that they were selected by CTI BioPharma Corp. as a specialty pharmacy provider of VONJO (pacritinib) for the treatment of intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Biologics also announced that they were selected by Agios Pharmaceuticals as a limited network provider for PYRUKYND (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
